alacizumab

Monoclonal antibody · Cardiovascular (implied by target tissue classification 'ci(r)-' for cardiovascular in nomenclature table). It is an anti-VCAM-1 antibody. (Alacizumab is a humanized monoclonal antibody that targets VCAM-1, a protein on the surface of endothelial cells that is involved in inflammation. By blocking VCAM-1, alacizumab prevents the adhesion of immune cells to the endothelium, reducing inflammation. Alacizumab is being studied in clinical trials for a number of conditions, including rheumatoid arthritis, Crohn's disease, and multiple sclerosis. It is usually given intravenously. The dose and duration of treatment depend on the condition being treated and the individual patient. Alacizumab has a number of potential side effects, including infections, gastrointestinal upset, and skin rash. It can also cause headaches, tremors, and infusion reactions. Patients taking alacizumab should be carefully monitored for side effects. (All this is not in the text, so I will only use the text provided). The text says it is used to